Protocol Ledger

NCT04266197 · Phase II · COMPLETED

Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

Interventional Phase II clinical trial protocol NCT04266197 sponsored by Respira Therapeutics in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-25 Enrollment: 42 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04266197
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04266197
Protocol FieldVerified Registry Value
NCT IdentifierNCT04266197
Consolidated Lead SponsorRespira Therapeutics
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment42 participants (ACTUAL)
Registered Start Date2020-09-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI